Trial · NCT07899853
In-situ vs Ex-situ Liver Preservation
NCT07899853, Not applicable, Recruiting, Leiden University Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. In-situ vs Ex-situ Liver Preservation. Trials, record NCT07899853. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899853
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- In-situ vs Ex-situ Liver Preservation
- NCT number
- NCT07899853
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 752 participants, estimated
- Lead sponsor
- Leiden University Medical Center
- Conditions
- Liver Disease (Alcoholic or Not), Transplantation
- Interventions
- In-situ perfusion: aNRP, Ex-situ perfusion: DHOPE/DHOPE-COR-NMP
- First posted
- 2026-10-28
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | one-year cumulative incidence of biliary complications | 1 year | Death censored incidence of biliary complications including biliary anastomotic strictures, post-transplant cholangiopathy and biliary leakages, all that necessitate intervention |
| Secondary | cost-effectiveness | 5 year | QALYs derived from EQ-5D-5L questionnaire measured at six time points: waitlist registration, and at six weeks, three, six, twelve and twenty-four months post-transplantation. If aNRP is estimated to lead to higher costs as well as better health outcomes or to lower costs and worse health outcomes, an incremental cost-effectiveness ratio (ICER) will be calculated (costs per QALY gained or savings per QALY lost). If not, one treatment will be considered dominant. As aNRP perfuses multiple organs at once, the overall costs per procedure and subsequent transplantations will be researched. |
| Secondary | Post transplant cholangiopathy rate | 1 year | Narrowing or irregularity of intra- or extra-hepatic donor bile duct excluding the biliary anastomosis leading to clinical symptoms or laboratory derangements in the absence of hepatic artery thrombosis for which an invasive intervention is required. |
| Secondary | patient QOL | 2 year | Health-Related Quality of Life via PROMIS questionnaire: Patient-Reported Outcomes Measurement Information System, that assesses seven core health domains using 4-item short form items plus one pain intensity item (scale 0-10, with 10 worse outcome). |
| Secondary | Patient mortality | 1 year | Recipient death |
| Secondary | Graft loss | 1 year | Failure of the liver allograft requiring either re-transplantation or leading to recipient mortality. |
| Secondary | post-transplant overall complications | 1 year | Also including vascular complications (hepatic artery and portal vein thrombosis) And complications graded as Clavien Dindo =\> 3a, and the comprehensive complication index |
| Secondary | duration of hospital and ICU stay | 1 year | In days |
| Secondary | Environmental Demand | 1 year | Environmental Demand: Measured in global hectares (gha). Converts all physical inputs (Greenhouse Gas Emissions: Measured in kg CO₂e, Electricity: Measured in kWh an Consumables \& Waste: Measured in kg of waste and liters (L) of fluids) into the total biophysical land area required to support each distinct protocol. |
| Secondary | Liver utilization rate | 1 year | How many livers are transplanted and still functioning from organ offer to 1 year post transplantation. It takes in account the acceptance rate, discard rate, transplant rate and 1-year survival. |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899853
GET https://conductscience.org/api/trials/v1/NCT07899853/registered?page=2